Amgen's ( AMGN) shares gained 3.5% after an analyst raised his price target on the stock, saying a competitive threat appears to be waning.

Bear Stearns analyst Mark Schoenebaum said papers filed Friday put Amgen's patent suit against Roche's competing drug Cera in a better light. He said the documents suggest Cera is similar enough to Amgen's Epo to prevent Roche from launching Cera in the U.S.

Amgen should reach a year-end price target of $83, says Schoenebaum. He previously set a price target of $77. The analyst upgraded the stock to outperform from peer perform two weeks ago.

"We increased the probability Cera does not launch in the U.S. from 25% to 60%," the analyst wrote in a research report Monday. "Additional upside to our estimates could come with more definitive evidence Cera will not launch in the U.S."

Shares were up $2.58 to $76.83 Monday morning.

Bear Stearns has received noninvestment banking compensation from Amgen, and the analyst or one of his family members has a long position on the stock, the firm says.

If you liked this article you might like

Spain to Play Netherlands for World Cup

Spain to Play Netherlands for World Cup

Wal-Mart: Analysts' Upgrades, Downgrades

Wal-Mart: Analysts' Upgrades, Downgrades

Netherlands Advances to World Cup Final

Netherlands Advances to World Cup Final

Apple: Analysts' Upgrades, Downgrades

Apple: Analysts' Upgrades, Downgrades

World Markets Mostly Lower Monday

World Markets Mostly Lower Monday